Atyr Pharma shares closed at $4.94 on Friday, 30 October, their highest close in a year and 370.5% above the previous 52-week high of $1.05 set on 19 February 2026. The shares have risen 407.7% over the past year, excluding dividends.
Atyr Pharma's share price over the year
Over the previous 52 weeks the shares closed between $0.12 and $1.05, a range entirely below today's close. Over longer periods the shares are up 295.2% over three years and down 42.8% over five years, excluding dividends.
What Atyr Pharma's latest figures show
Revenue over the twelve months to Q4 2025 was $190,000, which fell 19.1% on the year before; that growth rate was up 0.0 percentage points on the rate a quarter earlier, so the pace of decline held steady. The trailing operating margin was negative, at −40856.3%, down 11956.7 percentage points from a year earlier, and the company made a net loss of $60.8 million over the twelve months. Operating cash flow over the twelve months was −$54.5 million; capital spending of $279,000, or 40.5% of revenue, pushed free cash flow to −$54.8 million, a margin of −32664.7% of revenue, down 3224.7 percentage points from a year earlier.
Where Atyr Pharma's figures sit in its own record
Today's free-cash-flow margin of −32664.7% is higher than 8% of the company's own past quarterly readings, which have ranged from −33154.2% to −143.4%. The operating margin of −40856.3% is likewise higher than 8% of past readings, spanning −41395.3% to −152.2%.
What Atyr Pharma's next report has to show
A 52-week high says where the market's price has gone, not why. The next results will show whether the trends in the filings above support it.